Every 10-Q that Owens & Minor, Inc. (OMI) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow OMI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full OMI filings page.
Accendra Health, Inc. reported a net loss from continuing operations of $6.5 million, or $0.08 per share, for the quarter ended March 31 2026, compared with a loss of $3.8 million a year earlier. Net revenue declined 6.8% to $627.8 million, mainly due to terminated contracts with a major commercial payor that represented $37 million, or 6%, of quarterly revenue and nearly all capitation revenue.
Operating income was $17.1 million, helped by a $52 million gain on sales of patient service equipment linked to the payor exit and lower exit and realignment costs, but higher interest expense of $32.3 million pushed results into a loss. Cash flow from operating activities was an outflow of $50.1 million, while cash and cash equivalents increased to $336.9 million after equipment sale proceeds and additional revolver borrowings.
The company remains highly leveraged, with total debt of $2.10 billion against a balance sheet deficit of $464.8 million. A substantial portion of debt, including Term Loan A and the revolving credit facility, is classified as current due to 2027 maturities. Management has obtained creditor commitments for a “Balance Sheet Optimization Transaction” to refinance Term Loan A into new 9.000% senior secured first lien notes due 2032, amend and extend the revolver to 2030, and exchange the 2029 and 2030 unsecured notes into new secured notes, and believes this will provide sufficient liquidity over the next twelve months.
Owens & Minor (OMI) filed its Q3 2025 10‑Q, highlighting modest growth in continuing operations but large losses tied to the pending divestiture of its Products & Healthcare Services (P&HS) segment. Net revenue from continuing operations was $697,264 for the quarter, up slightly from $686,846. Continuing operations posted an operating income of $26,470, but interest and other items drove a loss before taxes of $(3,635).
The company recorded a Q3 net loss of $(150,276), largely due to discontinued operations. Year‑to‑date, the net loss reached $(1,044,316), reflecting a $771,640 loss on classification of P&HS as held‑for‑sale and a $106,389 goodwill impairment. OMI also paid an $80,000 transaction breakage fee for terminating a prior acquisition.
On October 7, 2025, OMI signed an agreement to sell P&HS for $375 million in cash, retain a 5% equity interest, and included termination fees of $9.4 million or $19 million; closing is expected in the first quarter of 2026, subject to customary approvals. As of September 30, 2025, total debt was $2,115,261 with $270,700 drawn on the revolver and $280,000 due within twelve months. Equity swung to a deficit of $(429,507). Concentration risk rose as the largest commercial payor plans to terminate contracts representing $242,000 (12%) of nine‑month net revenue, including $173,000 of capitation revenue.
Owens & Minor reported consolidated results showing continuing operations revenue rose to $681.9 million for the quarter and $1.356 billion for the six months, up from $660.4 million and $1.298 billion a year earlier. Continuing operations produced an operating loss of $39.7 million for the quarter and a pre-tax loss of $84.9 million, after recording an $80 million transaction breakage fee and acquisition-related charges.
The company classified its Products & Healthcare Services (P&HS) segment as discontinued operations and held-for-sale, recognizing a $106.4 million goodwill impairment and a $649.1 million loss on classification, contributing to a quarterly net loss of $869.1 million and basic loss per share of $11.30. Total assets were $4.15 billion with total liabilities of $4.44 billion, resulting in a deficit equity of $281.0 million at June 30, 2025. The divestiture process is described as in the final stages.